413 related articles for article (PubMed ID: 15872348)
1. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
Henze M; Dimitrakopoulou-Strauss A; Milker-Zabel S; Schuhmacher J; Strauss LG; Doll J; Mäcke HR; Eisenhut M; Debus J; Haberkorn U
J Nucl Med; 2005 May; 46(5):763-9. PubMed ID: 15872348
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U
J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic analysis of [
Bashir A; Vestergaard MB; Binderup T; Broholm H; Marner L; Ziebell M; Fugleholm K; Mathiesen T; Kjær A; Law I
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2577-2588. PubMed ID: 32170347
[TBL] [Abstract][Full Text] [Related]
4. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
5. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
Milker-Zabel S; Zabel-du Bois A; Henze M; Huber P; Schulz-Ertner D; Hoess A; Haberkorn U; Debus J
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):222-7. PubMed ID: 16488553
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ
J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
8. Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.
Acker G; Kluge A; Lukas M; Conti A; Pasemann D; Meinert F; Anh Nguyen PT; Jelgersma C; Loebel F; Budach V; Vajkoczy P; Furth C; Baur ADJ; Senger C
Neurosurg Focus; 2019 Jun; 46(6):E9. PubMed ID: 31153151
[TBL] [Abstract][Full Text] [Related]
9. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
10. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
[TBL] [Abstract][Full Text] [Related]
11. The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas.
Nathoo N; Ugokwe K; Chang AS; Li L; Ross J; Suh JH; Vogelbaum MA; Barnett GH
J Neurooncol; 2007 Jan; 81(2):167-74. PubMed ID: 16850106
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
[TBL] [Abstract][Full Text] [Related]
13. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
14. Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy.
Graf R; Nyuyki F; Steffen IG; Michel R; Fahdt D; Wust P; Brenner W; Budach V; Wurm R; Plotkin M
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):68-73. PubMed ID: 22575489
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
16. Improved Detection of Postoperative Residual Meningioma with [
Bashir A; Larsen VA; Ziebell M; Fugleholm K; Law I
Clin Cancer Res; 2021 Apr; 27(8):2216-2225. PubMed ID: 33526423
[TBL] [Abstract][Full Text] [Related]
17. Pearls and Pitfalls in Interpretation of 68Ga-DOTATOC PET Imaging.
Bashir A; Broholm H; Clasen-Linde E; Vestergaard MB; Law I
Clin Nucl Med; 2020 Jun; 45(6):e279-e280. PubMed ID: 32332303
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
19. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
20. The usefulness of [
Wang P; Liu S; Li X; Liu X; Li S; Wu Z; Cheng X
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):218-225. PubMed ID: 37682301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]